CytoDyn Inc. (CYDY) Research

CytoDyn Inc. functions as a biotechnology enterprise currently in its clinical development phase. The company primarily concentrates on crafting therapies for a variety of medical conditions, leveraging leronlimab – an innovative humanized monoclonal antibody designed to interact with the CCR5 receptor. This experimental drug is being explored for its potential applications in human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), various oncological diseases, and coronavirus disease (COVID-19). In addition, leronlimab is undergoing a Phase 1b/2 clinical investigation specifically for metastatic triple-negative breast cancer. Established in 2002, and previously operating as RexRay Corporation, CytoDyn Inc. is headquartered in Vancouver, Washington.

Market snapshot

Symbol
CYDY
Price
$0.27
Day change
-1.42%
Market cap
$369.8M
P/E ratio
-8.88x
52-week range
0.21-0.4
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 1 month

Peer companies

  • BioInvent International AB (publ) (BOVNF)
  • Clinuvel Pharmaceuticals Limited (CLVLF)
  • Clinuvel Pharmaceuticals Limited (CLVLY)
  • Cellectis S.A. (CMVLF)
  • Frontage Holdings Corporation (FGHQF)
  • Healios K.K. (HLOSF)
  • Hansa Biopharma AB (publ) (HNSBF)
  • Northwest Biotherapeutics, Inc. (NWBO)

Recent insider activity

  • Urbach Tanya Durkee — A-Award (574385 shares) on 2026-03-20
  • SIMES STEPHEN M — A-Award (574385 shares) on 2026-03-20
  • Ndhlovu Lishomwa C — A-Award (574385 shares) on 2026-03-20
  • Lalezari Jacob P — A-Award (4874691 shares) on 2026-03-20
  • Hoffman Robert E. — A-Award (4874691 shares) on 2026-03-20

Open CytoDyn Inc. (CYDY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.